Colgate-Palmolive (CL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended December 2025, Colgate-Palmolive (CL) reported revenue of $5.23 billion, up 5.8% over the same period last year. EPS came in at $0.95, compared to $0.91 in the year-ago quarter.The reported revenue represents a surprise of +2.79% over the Zacks Consensus Estimate of $5.09 billion. With the consensus EPS estimate being $0.91, the EPS surprise was +4.02%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Colgate-Palmolive performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net Sales- Oral, Personal and Home Care- North America: $1.02 billion compared to the $1.02 billion average estimate based on five analysts. The reported number represents a change of -1.5% year over year.Net Sales- Oral, Personal and Home Care- Latin America: $1.25 billion versus the five-analyst average estimate of $1.18 billion. The reported number represents a year-over-year change of +12.8%.Net Sales- Oral, Personal and Home Care- Africa/Eurasia: $309 million versus the five-analyst average estimate of $293.22 million. The reported number represents a year-over-year change of +14.9%.Net Sales- Oral, Personal and Home Care- Europe: $734 million versus $707.71 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +9.9% change.Net Sales- Oral, Personal and Home Care- Asia Pacific: $722 million compared to the $724.66 million average estimate based on five analysts. The reported number represents a change of -0.3% year over year.Net Sales- Pet Nutrition: $1.2 billion versus the five-analyst average estimate of $1.16 billion. The reported number represents a year-over-year change of +4.9%.Net Sales- Total Oral, Personal and Home Care: $4.03 billion versus the five-analyst average estimate of $3.92 billion. The reported number represents a year-over-year change of +6.1%.Operating profit- Pet Nutrition: $286 million versus the three-analyst average estimate of $278.19 million.Operating profit- Total Oral, Personal and Home Care: $999 million compared to the $993.46 million average estimate based on three analysts.View all Key Company Metrics for Colgate-Palmolive here>>>Shares of Colgate-Palmolive have returned +7.9% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.See Our Newest 5 Stocks Set to Double Picks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Colgate-Palmolive Company (CL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks